M&A Deal Summary

Ultragenyx Acquires Dimension Therapeutics

On October 3, 2017, Ultragenyx acquired life science company Dimension Therapeutics from Eight Roads for 151M USD

Acquisition Highlights
  • This is Ultragenyx’s 1st transaction in the Life Science sector.
  • This is Ultragenyx’s largest (disclosed) transaction.
  • This is Ultragenyx’s 1st transaction in the United States.
  • This is Ultragenyx’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2017-10-03
Target Dimension Therapeutics
Sector Life Science
Buyer(s) Ultragenyx
Sellers(s) Eight Roads
Deal Type Add-on Acquisition
Deal Value 151M USD
Advisor(s) MTS Health Partners LP (Financial)
Goodwin Procter (Legal)

Target

Dimension Therapeutics

Cambridge, Massachusetts, United States
Dimension Therapeutics is a developer of new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology. Dimension Therapeutics was founded in 2013 and is based in Cambridge, Massachusetts.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ultragenyx

Novato, California, United States
Category Company
Founded 2010
Sector Life Science
Employees1,276
Revenue 434M USD (2023)
DESCRIPTION

Ultragenyx is a biopharmaceutical company committed to bringing to market novel products to treat rare and ultra-rare diseases, focusing on serious, debilitating genetic diseases. Ultragenyx was founded in 2010 and is based in Novato, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Eight Roads

Investor

Category Private Equity Firm
Founded 1969
Size Small
Type Sector Focused
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.

DEAL STATS #
Overall 30 of 99
Sector (Life Science) 20 of 49
Type (Add-on Acquisition) 14 of 45
State (Massachusetts) 8 of 26
Country (United States) 17 of 60
Year (2017) 4 of 6
Size (of disclosed) 14 of 19
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-09-28 Stockpile

Palo Alto, California, United States

Stockpile is a platform service enabling people to buy stock by the dollar or give it as a gift. Stockpile was founded in 2010 and is based in Palo Alto, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-10-11 Symbiomix Therapeutics

Newark, New Jersey, United States

Symbiomix Therapeutics is a privately held company focused on bringing innovative therapies to market for gynecologic infections that can have serious health consequences. Symbiomix Therapeutics was founded in 2012 and is based in Newark, New Jersey.

Buy $150M
Mergr

Product

Company

Legal